Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Royalmount and NCI begin biomarker cancer study
Royalmount Pharma is collaborating with the NCI under a clinical trial agreement for the evaluation of the drug RM1812 as a cancer chemopreventive agent against colorectal cancer. Chemoprevention
Royalmount Pharma is collaborating with the NCI under a clinical trial agreement for the evaluation of the drug RM1812 as a cancer chemopreventive agent against colorectal cancer. Chemoprevention
Merck said the settlement resolves all of the issues that were in dispute. Under the agreement, the final net cash cost to Merck covers federal tax, net interest
BrainStorm's adult stem cell technology has shown efficacy in animal models of Parkinson's disease in previous preclinical trials. In those studies, stem cells derived from human bone-marrow were
“I believe these results are very promising and may provide a much needed alternative to current topical treatments such as corticosteroids,” said Professor Arieh Ingber, the head of
Hylenex recombinant is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs. Under the terms of the agreements, Baxter will pay Halozyme an
In the trial patients with relapsed or refractory chronic lymphocytic leukemia (CLL) received fludarabine plus cyclophosphamide chemotherapy with or without Genasense. This trial achieved its primary endpoint, which
While terms of the agreement are not disclosed, the focus of the agreement will be on studying the use of Favrille's active immunotherapy, FavId, in conjunction with Berlex's
PS433540 is the only dual-acting angiotensin and endothelin receptor antagonist (DARA) compound in development and it possesses two clinically validated mechanisms of action in a single compound. The
The financial terms of this agreement include total milestone payments to GW of up to GBP273 million as well as commercial supply price and royalty. Otsuka will pay
The agreement will cover the Asia Pacific region and will include Thailand, the Philippines, Malaysia, Indonesia, China, Japan, and parts of Australia. Approximately 30,000 to 50,000 people suffer